Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.34 |
| ▸ | CCR9 | P51686 | 2/20 | 0.34 |
| ▸ | BCL2 | P10415 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822377 | 1.00 | MCL1 (0.34) | MCL1MTNR1AMTNR1BCCR9BCL2 | |
| SCHEMBL25017969 | 0.94 | MTNR1A (0.35) | MCL1MTNR1AMTNR1BPDK2ACHE | |
| SCHEMBL21822737 | 0.84 | CTSS (0.42) | MCL1CCR9 | |
| SCHEMBL31689662 | 0.84 | CTSS (0.42) | MCL1CCR9 | |
| SCHEMBL25017971 | 0.80 | F10 (0.43) | MCL1BCL2 | |
| SCHEMBL21822112 | 0.80 | NQO2 (0.37) | MCL1CCR9 | |
| SCHEMBL31689687 | 0.80 | NQO2 (0.37) | MCL1CCR9 | |
| SCHEMBL21822553 | 0.79 | NQO2 (0.44) | MTNR1AMTNR1B | |
| SCHEMBL21822575 | 0.75 | F10 (0.42) | MCL1MTNR1AMTNR1BBCL2 | |
| SCHEMBL31689703 | 0.75 | F10 (0.42) | MCL1MTNR1AMTNR1BBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | MCL1 3593/4885MTNR1A 1514/4885MTNR1B 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.